How to interpret the approval of the CS014 study – an explanation for investors
March 17, 2026
Cereno Scientific today announced that the Swedish Medical Products Agency has approved the initiation of a clinical pharmacokinetic study with the drug candidate CS014. The study has been designed following dialogue with the U.S. Food and Drug Administration (FDA) and represents a regulatory step in the preparations for the planned Phase II trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD).
In this article, we explain what the approval means and how the study fits into the development of CS014.
What has been approved?
Cereno Scientific has received regulatory approval to conduct a Phase I pharmacokinetic study in which the drug candidate CS014 will be compared with valproic acid (VPA), a well-known HDAC inhibitor with extensive clinical use.
The study will be conducted in 14 healthy volunteers and will analyze how the drug is absorbed and circulates in the body following repeated dosing over seven days.
The purpose is to characterize the drug concentration in the blood at so-called steady state, when drug levels stabilize in the body after several days of treatment, and compare these results with corresponding data for VPA.
The study is a pharmacokinetic bridging study, a regulatory bridge into the next development phase, which may enable CS014 to move directly to a Phase IIb study.
The design is based on feedback from a pre-IND meeting with the FDA, during which the agency provided guidance regarding the data required ahead of the initiation of a Phase IIb study.
By generating comparative bioavailability data, Cereno Scientific may leverage the extensive clinical experience from VPA and thereby strengthen the safety package for CS014.
This means that the development program may proceed without additional safety studies and a Phase IIa study, thus simplifying and streamlining the path toward the next clinical phase. The program may therefore advance directly into Phase IIb, a larger efficacy study designed to confirm the clinical potential ahead of later-stage development.
How does this fit into the development of CS014?
CS014 is being developed for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a serious disease with limited treatment options and significant unmet medical need.
CS014 is a precision deuterated HDAC inhibitor developed within Cereno Scientific’s proprietary epigenetic platform. By targeting key disease processes, including fibrosis, pathological vascular remodeling, inflammation, and thrombosis, the goal is to influence the mechanisms driving disease progression.
This creates the possibility to not only to manage symptoms, but also to potentially impact the underlying disease progression across several cardiopulmonary diseases, with PH-ILD as the initial development focus.
The current study therefore represents an important step in strengthening the regulatory and clinical foundation ahead of the next development phase and contributes to a more efficient development pathway toward potential marketing approval.
What happens next?
The planned pharmacokinetic study comparing CS014 with VPA following repeated dosing will be conducted in Sweden and is expected to start shortly.
Results are anticipated in mid-2026 and will form part of the basis for the planned Phase IIb study in PH-ILD, which the company plans to initiate during the first quarter of 2027.
- Regulatory approval to initiate a pharmacokinetic Phase I study with CS014
- The study has been designed in dialogue with the FDA as a PK bridging study ahead of the next development phase
- The comparison with valproic acid (VPA) may replace additional safety studies and a Phase IIa study, while also contributing to a more efficient development pathway toward potential market approval
- The objective remains to initiate a Phase IIb study in PH-ILD during the first quarter of 2027